A pilot safety / tolerability study of Lenalidomide administered as monotherapy and in combination with standard chemotherapy for acute myeloid leukaemia / high-risk Myelodysplastic Syndrome with structural abnormalities of chromosome 5.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 27 Oct 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lenalidomide (Primary) ; Cytarabine; Daunorubicin; Etoposide
Indications Acute myeloid leukaemia; Myelodysplastic syndromes
Focus Adverse reactions; Therapeutic Use
Acronyms AML-LEN5

Most Recent Events

21 Jul 2019 Status changed from active, no longer recruiting to completed.
31 May 2012 Additional trial location (Scotland) identified as reported by UKCRN.
24 Mar 2012 Planned number of patients changed from 39 to 47 as reported by European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight